Inavolisib (Itovebi) is a new targeted therapy for HR+ HER2-negative metastatic breast cancer with a PIK3CA mutation.

Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances in breast cancer.

Trastuzumab deruxtecan with pertuzumab significantly extended progression-free survival in HER2-positive advanced breast cancer, compared to standard THP therapy, according to DESTINY-Breast09 trial ...

Dr Heather McArthur describes how ASCO 2025 showcased new standards of care in triple-negative and HER2-positive settings.

El fármaco está indicado en monoterapia para tratar a el cáncer de mama HER2 positivo no resecable y/o metastásico que hayan recibido uno o más regímenes previos anti-HER2.

In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses results from an interim analysis of the DESTINY-Breast09 trial, which were presented at ASCO Annual Meeting.The ...

Fam-trastuzumab deruxtecan-nxki (AstraZeneca and Daiichi Sankyo) Human epidermal growth factor receptor 2 (HER2)-directed antibody + topoisomerase inhibitor conjugate: Treatment of patients with ...

MADRID 4 Jun. (EUROPA PRESS) - Las compañías Daiichi Sankyo y AstraZeneca han anunciado que trastuzumab deruxtecán combinado con pertuzumab ha reducido en un 44 por ciento el riesgo de ...

Fam-trastuzumab deruxtecan-nxki (AstraZeneca and Daiichi Sankyo) Human epidermal growth factor receptor 2 (HER2)-directed antibody + topoisomerase inhibitor conjugate: ...

Tarantino P, Kim A, Hughes M, et al. Quantitative pre-treatment assessment of trastuzumab deruxtecan (T-DXd) antibody target (HER2) and payload target (topoisomerase 1, Topo1) to predict outcomes in ...

To further investigate the effects of SLC7A11 inhibition or cysteine limitation on trastuzumab primary-resistant HER2-positive breast cancer, JIMT1 xenograft mouse models were generated and then ...

El anticuerpo conjugado (ADC) trastuzumab deruxtecán de la Alianza Daiichi Sankyo y AstraZeneca muestra una mejora estadísticamente significativa y clínicamente relevante de la supervivencia ...